Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q1 2015

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q1 2015


  • Products Id :- GDPH0478QD
  • |
  • Pages: 140
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q1 2015

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q1 2015" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons To Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market.

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 11

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2015 15

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2015 15

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2015 18

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2015 19

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2015 20

2.4.1 AbbVie to Acquire Pharmacyclics for USD21 Billion 20

2.4.2 Actavis Raises USD21 Billion in Public Offering of Senior Notes 21

2.4.3 Pfizer to Acquire Hospira for USD17 Billion 21

2.4.4 UnitedHealth to Acquire Catamaran for USD12.8 Billion 22

2.4.5 Valeant Pharma Acquires Salix Pharma for USD10.9 Billion 22

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 25

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2015 25

3.1.1 Top M&A Deals in Q1 2015 26

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2014-Q1 2015 27

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2015 28

3.2.1 Top Initial Public Offerings in Q1 2015 29

3.2.2 Top Secondary Offerings in Q1 2015 30

3.2.3 Top PIPE Deals in Q1 2015 30

3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2014-Q1 2015 31

3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2014-Q1 2015 31

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2015 33

3.3.1 Top Venture Financing Deals in Q1 2015 34

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2015 35

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2015 36

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2014-Q1 2015 37

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2014-Q1 2015 38

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2014-Q1 2015 39

3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2015 40

3.4.1 Top Private Equity Deals in Q1 2015 41

3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2014-Q1 2015 42

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2015 43

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2015 43

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2014-Q1 2015 45

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2015 47

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2015 48

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2015 49

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2015 50

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2014-Q1 2015 51

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2014-Q1 2015 53

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (USD m), Q1 2014-Q1 2015 54

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2014-Q1 2015 55

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2015 57

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2015 57

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (USD m), Q1 2014-Q1 2015 59

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2015 60

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2015 61

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2015 61

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (USD m), Q1 2014-Q1 2015 62

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (USD m), Q1 2014-Q1 2015 64

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (USD m), Q1 2014-Q1 2015 66

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (USD m), Q1 2014-Q1 2015 67

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (USD m), Q1 2014-Q1 2015 69

6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 71

6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q1 2014-Q1 2015 71

6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q1 2014-Q1 2015 73

6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2014-Q1 2015 74

6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2014-Q1 2015 76

6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q1 2014-Q1 2015 77

6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q1 2014-Q1 2015 78

6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2014-Q1 2015 79

7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 80

7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2015 80

7.1.1 Oncology-Deals of the Quarter 81

7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2015 84

7.2.1 Central Nervous System-Deals of the Quarter 86

7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2015 89

7.3.1 Infectious Disease-Deals of the Quarter 90

7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2015 93

7.4.1 Immunology-Deals of the Quarter 95

7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2015 97

7.5.1 Metabolic Disorders-Deals of the Quarter 98

7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2015 100

7.6.1 Cardiovascular-Deals of the Quarter 101

7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2015 103

7.7.1 Gastrointestinal-Deals of the Quarter 104

7.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2015 106

7.8.1 Dermatology-Deals of the Quarter 107

7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2015 109

7.9.1 Respiratory-Deals of the Quarter 110

7.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2015 112

7.10.1 Ophthalmology-Deals of the Quarter 114

8 Deal Summary by Geography 117

8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2015 117

8.1.1 North America-Deals of the Quarter 119

8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2015 122

8.2.1 Europe-Deals of the Quarter 123

8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2015 125

8.3.1 Asia-Pacific-Deals of the Quarter 126

8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2015 128

8.4.1 Rest of the World-Deals of the Quarter 129

9 Pharmaceuticals & Healthcare, Global, Top Advisors 131

9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2014-Q1 2015 131

9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2014-Q1 2015 133

10 Appendix 135

11 Further Information 137

11.1 Methodology 137

11.2 About GlobalData 138

11.3 Disclosure information 139

11.4 Disclaimer 139

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USDm), Q1 2014-Q1 2015 15

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2015 18

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2015 19

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (USDm), Q1 2014-Q1 2015 25

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (USDm), by Therapy Area, Q1 2014-Q1 2015 27

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 28

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (USDm), , Q1 2014-Q1 2015 31

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 33

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2015 35

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2015 36

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, Q1 2014-Q1 2015 37

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 38

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 40

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, Q1 2014-Q1 2015 42

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 43

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 45

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (USD m), Q1 2014-Q1 2015 47

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), Q1 2014-Q1 2015 51

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2014-Q1 2015 53

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2014-Q1 2015 54

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (USD m), Q1 2014-Q1 2015 55

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 57

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2014-Q1 2015 59

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 62

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (USD m), Q1 2014-Q1 2015 64

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2014-Q1 2015 66

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (USD m), Q1 2014-Q1 2015 67

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2014-Q1 2015 69

Figure 29: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (USDm), Q1 2014-Q1 2015 71

Figure 30: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2014-Q1 2015 73

Figure 31: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2014-Q1 2015 74

Figure 32: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2014-Q1 2015 76

Figure 33: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2014-Q1 2015 77

Figure 34: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2014-Q1 2015 78

Figure 35: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2014-Q1 2015 79

Figure 36: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 80

Figure 37: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 84

Figure 38: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 89

Figure 39: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 93

Figure 40: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 97

Figure 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 100

Figure 42: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 103

Figure 43: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 106

Figure 44: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 109

Figure 45: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 112

Figure 46: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 117

Figure 47: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 122

Figure 48: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 125

Figure 49: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 128

Figure 50: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 131

Figure 51: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 133

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (USDm), Q1 2014-Q1 2015 17

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2015 19

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2015 20

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 26

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2015 26

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, , Q1 2014-Q1 2015 27

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USDm), Q1 2014-Q1 2015 29

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2015 29

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2015 30

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2015 30

Table 11: Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2014-Q1 2015 31

Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USDm), Q1 2014-Q1 2015 32

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 34

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2015 34

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2015 36

Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (USDm), Q1 2014-Q1 2015 37

Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 38

Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2014-Q1 2015 39

Table 19: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 41

Table 20: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2015 41

Table 21: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (USDm), Q1 2014-Q1 2015 42

Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 44

Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 46

Table 24: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (USD m), Q1 2014-Q1 2015 48

Table 25: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (USD m), Q1 2015 48

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2015 49

Table 27: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2015 50

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), Q1 2014-Q1 2015 52

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2014-Q1 2015 54

Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (USD m), Q1 2014-Q1 2015 56

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 58

Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (USD m), Q1 2014-Q1 2015 60

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2015 60

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2015 61

Table 35: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2015 61

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 63

Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (USD m), Q1 2014-Q1 2015 65

Table 38: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2014-Q1 2015 68

Table 39: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (USD m), Q1 2014-Q1 2015 70

Table 40: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value vs Median Deal Value, (USDm), Q1 2014-Q1 2015 72

Table 41: Pharmaceuticals & Healthcare, Global Acquisitions, Average P/E of Acquired Companies, Q1 2014-Q1 2015 73

Table 42: Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2014-Q1 2015 75

Table 43: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Operating Profit, Q1 2014-Q1 2015 76

Table 44: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Market Price Per Share, Q1 2014-Q1 2015 77

Table 45: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2014-Q1 2015 78

Table 46: Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2014-Q1 2015 79

Table 47: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 81

Table 48: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 85

Table 49: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 90

Table 50: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 94

Table 51: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 98

Table 52: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 101

Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 104

Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 107

Table 55: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 110

Table 56: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 113

Table 57: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 118

Table 58: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 123

Table 59: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 126

Table 60: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 129

Table 61: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 132

Table 62: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), Q1 2014-Q1 2015 134

Table 63: Pharmaceuticals & Healthcare, Deals� Key Financials, Global Acquisition Deals, Q1 2014-Q1 2015 135

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

select a license

Single User License
USD 1500 INR 97575
Site License
USD 3000 INR 195150
Corporate User License
USD 4500 INR 292725

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com